US 12,281,159 B2
TGFβ antibodies, methods and uses
Gregory J. Carven, Maynard, MA (US); Thomas Schurpf, Cambridge, MA (US); and Katherine Turner, Acton, MA (US)
Assigned to Scholar Rock, Inc., Cambridge, MA (US)
Filed by Scholar Rock, Inc., Cambridge, MA (US)
Filed on May 25, 2021, as Appl. No. 17/329,859.
Application 17/329,859 is a continuation of application No. 16/317,635, abandoned, previously published as PCT/US2017/042162, filed on Jul. 14, 2017.
Claims priority of provisional application 62/371,355, filed on Aug. 5, 2016.
Claims priority of provisional application 62/362,393, filed on Jul. 14, 2016.
Prior Publication US 2021/0277100 A1, Sep. 9, 2021
Int. Cl. C07K 16/22 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12N 9/00 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 38/18 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); C07K 16/28 (2013.01); C12N 9/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/32 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 26 Claims
 
1. An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof specifically binds to human proTGFβ1 in a complex with human glycoprotein A repetitions predominant (proTGFβ1-GARP complex), wherein the antibody or antigen-binding fragment thereof comprises:
a. a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9; or
b. a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15.